Malcolm Boyce

3.3k citations

107 papers · 2.4k indexed · h-index 29

Impact in

Gastroenterology top 2%
- Gastroesophageal reflux and treatments
Immunology and Allergy top 5%
- Allergic Rhinitis and Sensitization

Papers in ⓘ

Gastroenterology 13
- Gastroesophageal reflux and treatments 11
Immunology and Allergy 9
- Allergic Rhinitis and Sensitization 8

Co-authors: Steve Warrington (30 shared papers)Kathy Baisley (5 shared papers)Peter J. Barnes (4 shared papers)Brian O’Connor (3 shared papers)Trevor T. Hansel (3 shared papers)D. Mark Pritchard (7 shared papers)Andrea Varró (7 shared papers)Stephen T. Holgate (2 shared papers)
Journals: British Journal of Clinical Pharmacology (16 papers)European Journal of Clinical Pharmacology (8 papers)Alimentary Pharmacology & Therapeutics (4 papers)Gastroenterology (3 papers)The Journal of Clinical Pharmacology (3 papers)
Partner nations: United Kingdom United States Norway

In The Last Decade

Malcolm Boyce

105 papers receiving 2.3k citations

Peers

Countries citing papers authored by Malcolm Boyce

Since Specialization

Citations

This map shows the geographic impact of Malcolm Boyce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Boyce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Boyce more than expected).

Fields of papers citing papers by Malcolm Boyce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Boyce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Boyce. The network helps show where Malcolm Boyce may publish in the future.

Co-authors

The 25 scholars most cited alongside Malcolm Boyce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Malcolm Boyce Line = papers co-authored together Malcolm Boyce links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 107 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response The Lancet ·Shannon A. Bryan, Brian O’Connor, Salah Matti, Margaret J Leckie, Varsha Kanabar, Jamey Khan, Steve Warrington, Louis M. Renzetti, Alexis Rames, Juergen A Bock, Malcolm Boyce, Trevor T. Hansel, Stephen T. Holgate, Peter J. Barnes	2000	282
2	Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate Molecular Therapy ·Tracy Zimmermann, Verena Karsten, Amy Chan, Joseph Chiesa, Malcolm Boyce, Brian R. Bettencourt, Renta Hutabarat, Saraswathy V. Nochur, Akshay Vaishnaw, Jared Gollob	2017	157
3	Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A Alimentary Pharmacology & Therapeutics ·Reidar Fossmark, Øystein Sørdal, Constantin S. Jianu, Gunnar Qvigstad, Ivar S. Nordrum, Malcolm Boyce, Helge L. Waldum	2012	81
4	The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography Psychopharmacology ·C. J. Bench, Adriaan A. Lammerstma, Paul M. Grasby, Raymond J. Dolan, R. S. J. Frackowiak, SJ Warrington, Malcolm Boyce, K. Gunn, L. Y. Brannick	1996	69
5	Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects British Journal of Pharmacology ·Malcolm Boyce, Steve Warrington, B Cortezi, Stefan Zöllner, S Vauléon, Dorine W. Swinkels, Luciana Summo, Frank Schwoebel, Kai Riecke	2016	68
6	Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects Alimentary Pharmacology & Therapeutics ·Steve Warrington, Kathy Baisley, Malcolm Boyce, Bina Tejura, Anna Morocutti, Neil Miller	2002	61
7	Crossover study of the haematological effects and pharmacokinetics of glycosylated and non‐glycosylated G‐CSF in healthy volunteers British Journal of Haematology ·Michael Watts, Ian E. Addison, S. G. Long, Sigan L. Hartley, Steve Warrington, Malcolm Boyce, David C. Linch	1997	57
8	Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo‐controlled, double‐blind, crossover study British Journal of Clinical Pharmacology ·Malcolm Boyce, Kathy Baisley, Steve Warrington	2011	57
9	Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus Oncotarget ·Yoomi Lee, Aleksandra M. Urbanska, Yoku Hayakawa, Hongshan Wang, Andrew S. Au, Aesis Luna, Wenju Chang, Guangchun Jin, Govind Bhagat, Julian A. Abrams, Richard A. Friedman, Andrea Varró, Kenneth K. Wang, Malcolm Boyce, Anil K. Rustgi, Antonia R. Sepulveda, Michael Quante, Timothy C. Wang	2016	57
10	Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis British Journal of Clinical Pharmacology ·Malcolm Boyce, Andrew R. Moore, Liv Sagatun, Bryony N. Parsons, Andrea Varró, Fiona Campbell, Reidar Fossmark, Helge L. Waldum, D. Mark Pritchard	2016	47
11	Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660) British Journal of Clinical Pharmacology ·Bruce E. Miller, Ruth J. Mayer, Navin Goyal, Joanne Bal, Nigel Dallow, Malcolm Boyce, Donald C. Carpenter, Alison Churchill, Teresa Heslop, Aili L. Lazaar	2017	47
12	A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition Journal of Neural Transmission ·Anthony Clarke, E S Johnson, Nicholas Mallard, T. H. Corn, A. E. Johnston, Malcolm Boyce, Steve Warrington, Douglas G MacMahon	2003	45
13	Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis PLoS ONE ·Andrew R. Moore, Malcolm Boyce, Islay Steele, Fiona Campbell, Andrea Varró, D. Mark Pritchard	2013	43
14	Tolerability, pharmacokinetics and pharmacodynamics of TA‐8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects British Journal of Clinical Pharmacology ·J. Ford, Matt Lawson, D. E. Fowler, Nobuko Maruyama, Seiji Mito, Koichi Tomiyasu, Shuji Kinoshita, Chisa Suzuki, Atsuhiro Kawaguchi, Patrick Round, Malcolm Boyce, Steve Warrington, Werner Weber, Sander van Deventer, John J.P. Kastelein	2014	43
15	Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942 EBioMedicine ·Gary Burgess, Malcolm Boyce, Margaret M. Jones, Lars Larsson, Mark Main, Frazer Morgan, P. A. Phillips, Alison Scrimgeour, Foteini Strimenopoulou, Pavan Vajjah, Miren Zamacona, Roger Palframan	2018	42
16	Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects British Journal of Clinical Pharmacology ·Adeep Puri, Andrew Niewiarowski, Yasumasa Arai, H Nomura, Mark E. Baird, Isobel Dalrymple, Steve Warrington, Malcolm Boyce	2017	42
17	A five way crossover human volunteer study to compare the pharmacokinetics of paracetamol following oral administration of two commercially available paracetamol tablets and three development tablets containing paracetamol in combination with sodium bicarbonate or calcium carbonate European Journal of Pharmaceutics and Biopharmaceutics ·T. J. Grattan, Rachel Hickman, Anne Darby-Dowman, Marshall A. Hayward, Malcolm Boyce, Steve Warrington	2000	40
18	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers The Journal of Clinical Pharmacology ·Carol Addy, Susie Li, Nancy Agrawal, Julie A. Stone, Anup Majumdar, L. Zhong, Hankun Li, Jinyu Yuan, Andrea Maes, Paul Rothenberg, Josée Côté, Kim Rosko, Corinne E Cummings, Steve Warrington, Malcolm Boyce, Keith Gottesdiener, Aubrey Stoch, John A. Wagner	2008	39
19	The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development Regulatory Peptides ·Mark Kidd, Z-L Siddique, Ignat Drozdov, Björn Gustafsson, Robert L. Camp, J.W. Black, Malcolm Boyce, Irvin Modlin	2010	39
20	Coadministration of Orally Inhaled Zanamivir with Inactivated Trivalent Influenza Vaccine Does Not Adversely Affect the Production of Antihaemagglutinin Antibodies in the Serum of Healthy Volunteers Clinical Pharmacokinetics ·Alison Webster, Malcolm Boyce, Sally Edmundson, Irene Miller	1999	38

About Malcolm Boyce

Malcolm Boyce is a scholar working on Gastroenterology, Immunology and Allergy, Physiology, Hematology and Surgery, having authored 107 papers that have together received 2.4k indexed citations. Recurring topics across this work include Helicobacter pylori-related gastroenterology studies (22 papers), Neuroendocrine Tumor Research Advances (13 papers), Asthma and respiratory diseases (11 papers), Gastroesophageal reflux and treatments (11 papers), Allergic Rhinitis and Sensitization (8 papers), Pharmaceutical studies and practices (7 papers), Respiratory and Cough-Related Research (7 papers) and Receptor Mechanisms and Signaling (6 papers). The work is most often cited by research in Gastroenterology (214 citations), Immunology and Allergy (183 citations), Physiology (560 citations), Immunology (363 citations) and Oncology (396 citations). Malcolm Boyce has collaborated with scholars based in United Kingdom, United States and Norway. Frequent co-authors include Steve Warrington, Kathy Baisley, Peter J. Barnes, Brian O’Connor, Trevor T. Hansel, D. Mark Pritchard, Andrea Varró, Stephen T. Holgate, Varsha Kanabar and Helge L. Waldum. Their work appears in journals such as British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Alimentary Pharmacology & Therapeutics, Gastroenterology and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact